SHINE announces EU marketing authorization for its non-carrier-added Lu-177.

"EMA approval opens the door for SHINE’s radioisotope Lu-177 to be used in developing radioligand therapies at scale, and ultimately support the expanded reach of nuclear medicine to patients. Combined with the isotope manufacturing and distribution operation we run for North American hospitals and imaging centers, SHINE now serves both sides of nuclear medicine," said Michael Rossi, CEO of SHINE SPECT LLC.

SHINE is sharing an important update: “SHINE Secures European Marketing Authorization for Ilumira, Latest Step in Building Integrated Nuclear Medicine Platform" Read the full release below: